… biomarker to identify Parkinson’s disease patients as early as possible is urgently needed. Nerve cells near the … disease causes and may open new possibilities for diagnosis and treatment. Project Description: We will … what causes Parkinson’s disease, how we can diagnose it as early as possible and how to cure patients from Parkinson’s …

… in its Partnering Program. Selected from the most promising research projects in the MJFF portfolio, Partnering Program … through the pipeline of drug development, and eventually into patients’ hands. Non-confidential overviews of select … for full-blown Parkinson’s could also be used for early detection of PD. ·         Sapiens is working on …

… The Michael J. Fox Foundation (MJFF) joins the research community in mourning the passing of Robert E. … a reviewer for the Clinical Discovery Awards , a critical early initiative to help move promising ideas into clinical testing toward the development of breakthrough …

… industry partners and patients gathered in New York City in early May for the annual Parkinson’s Progression Markers … 17 with a LRRK2 mutation). The other measure is a clinical diagnosis from the investigator. Of those 33, nine were … and building toward new insights.   Marek noted the move into digital health data capture with the addition of the …

… member of the UCSF Institute of Human Genetics. His primary research focus is on the pathogenesis of Parkinson disease. … familial forms of the disease as a way of gaining insight into fundamental pathways leading to Parkinson's disease. These pathways then become targets of early diagnostic and therapeutic interventions. Dr. Nussbaum …

… Parkinson’s disease. Levodopa is a drug that is converted into dopamine in the brain, and carbidopa is a drug that … as part of our de-risking strategy, which provides early funding to promising therapeutics to strengthen the … progress of this therapy.    Claire Cole, PhD Director of Research Communications …